Chronic inflammation leaves long-lasting impression on gut stem cells, increasing colorectal cancer risk

NIH-funded animal study finds heritable memories of damage persisted in cells months after inflammation ceased. The institutional report frames the development in practical terms and ties it to the broader mission or observing effort.

This matters because biology becomes more informative when an observed effect begins to look like a mechanism rather than an isolated pattern. The gap between identifying a correlation in biological data and understanding the causal chain that produces it is routinely underestimated, and the history of biomedical research is populated with associations that collapsed when the mechanism was sought and not found. A result that comes with a proposed mechanism, even a partial one, is more useful than a purely descriptive finding because it generates testable predictions that can narrow the hypothesis space. In a new study, funded in part by the National Institutes of Health (NIH), researchers have uncovered a molecular mechanism that could explain how chronic gut inflammation may. The authors, based at the Broad Institute of MIT and Harvard, analyzed the animals and organoids derived from their injured tissue, finding that the damage caused alterations in.

The researchers closely examined more than 52, 000 individual cells across the animals, identifying one epigenetic change that stood out from the rest. The results suggested that colitis led to an alteration in colonic stem cells that increased the activity of AP-1 transcription factors, which are known to steer cellular.

This memory persisted in the epigenomes of cells for more than 100 days after the authors removed colitis-inducing chemicals from the animals. They confirmed that the memory of AP-1 was heritable, with colonic stem cells passing it down to new cells as they divided.

The authors found that a slew of regenerative activities associated with AP-1 were in overdrive within tumors of recovered animals. When they blocked AP-1 activity, the pro-cancer effect of colitis disappeared, suggesting that this group of molecules may be a central player linking chronic inflammation in the.

The broader interest lies in whether the reported effect points toward a real mechanism and not merely a reproducible but unexplained association. Biology has learned from decades of biomarker failures that correlation, even robust correlation, is not a substitute for mechanistic understanding. A pathway that can be traced from molecular interaction to cellular response to organismal phenotype provides a far stronger foundation for intervention than a statistical association discovered in a large dataset, however well the statistics are done.

This study is part of the Cancer Grand Challenges team PROSPECT which is supported by NCI grants 1OT2CA297577 and 3OT2CA297577, Cancer Research UK, the French National Cancer. This research was also funded by the National Human Genome Research Institute (NHGRI) through grant UM1HG011986 and by the National Institute of Diabetes and Digestive and Kidney.

Because the account originates with NIH News Releases, it functions best as a primary institutional report that is close to the data and operations, not as independent scientific validation. Institutional communications are produced by organizations with legitimate interests in presenting their work in a favorable light, which does not make them unreliable but does make them partial. Details that complicate the narrative, including instrument limitations, unexpected failures and results below projections, tend to be minimized relative to progress messages. Technical documentation and peer-reviewed publications, where they exist, provide the complementary layer that institutional releases cannot substitute.

The next step is to test whether the effect repeats across different methods, cell types, model organisms and experimental conditions. Reproducibility is the first test, but mechanistic dissection is the second, and a result that passes both has a substantially better chance of translating into something clinically or biotechnologically useful. The path from a laboratory finding to an applied outcome typically takes a decade or more, and most findings do not complete it; the current result sits at the beginning of that process.

Source